# A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT02123758** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Aragon Pharmaceuticals, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** JNJ-56021927

## Key facts

- **NCT ID:** NCT02123758
- **Lead sponsor:** Aragon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-07-09
- **Primary completion:** 2016-06-27
- **Final completion:** 2027-12-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02123758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02123758, "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02123758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*